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Abstract 
 
The inhibitory receptor FcγRIIb regulates B-cell functions. Genetic studies have 
associated Fcgr2b polymorphisms and lupus susceptibility in both humans and 
murine models, in which B cells express reduced FcγRIIb levels. Furthermore, 
FcγRIIb absence results in lupus on the appropriate genetic background, and 
lentiviral-mediated FcγRIIb overexpression prevents disease in the NZM2410 lupus 
mouse. The NZM2410/NZW allele Fcgr2b is, however, located in-between Sle1a and 
Sle1b, two potent susceptibility loci, making it difficult to evaluate Fcr2bNZW 
independent contribution. By using two congenic strains that each carries only Sle1a 
(B6.Sle1a(15–353)), or Fcr2bNZW in the absence of Sle1a or Sle1b (B6.Sle1(111–
148)), we show that the Fcr2bNZW allele does not upregulate its expression on 
germinal center B cells and plasma cells, as does the C57BL/6 allele on 
B6.Sle1a(15–353) B cells. Furthermore, in the absence of the flanking Sle1a and 
Sle1b, Fcr2bNZW does not produce an autoimmune phenotype, but is associated with 
an increased number of class-switched plasma cells. These results show that while a 
lower level of FcγRIIb does not by itself induce the development of autoreactive B 
cells, it has the potential to amplify the contribution of autoreactive B cells induced by 
other lupus-susceptibility loci by enhancing the production of class-switched plasma 
cells.  
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Introduction  
 
Both forward and reverse genetic approaches in lupus patients and in murine models 
have shown a high level of complexity in the mechanisms by which genetic variation 
contributes to lupus susceptibility.
1 
A number of linkage and association studies have 
associated the Fcγ receptors (FcgRs) with lupus susceptibility in both humans and 
mice. Among the FcγRs, FcγRIIb plays a unique role in inducing inhibitory signals in 
B cells upon immune complex binding.
2 
In humans, a -343 G/C promoter 
polymorphism and a Ile232Thr trans-membrane polymorphism, both associated with 
loss of function, have been associated with lupus.3 The strength of the association 
between each of these polymorphisms and disease varied among populations, most 
likely due to interactions with other susceptibility alleles segregating differently 
among these populations. Functionally, two recent studies have reported that lupus 
patients present a defective upregulation of FcγRIIb expression in selected late B-
cell developmental stages, namely, memory B cells and plasma cells (PC).4,5 In the 
mouse, FcγRIIb is required for the maintenance of systemic tolerance on a C57BL/6 
(B6) background,6 and a B-cell receptor l transgenic model has suggested that it 
constitutes a checkpoint at the post-germinal center (GC)/plasma cell stage.7 
Several lupus-prone strains show reduced FcγRIIb levels attributed to a promoter 
region polymorphism for NZB, BXSB and MRL.8,9 However, using B6.Sle1/NZW and 
NZW mice, we have recently shown that failed upregulation of FcγRIIb on GC B cells 
is not associated with the promoter region polymorphism, but rather with additional 
polymorphisms in the putative regulatory regions 3 and 4 in the third intron shared by 
both NZB and NZW alleles.10 A direct demonstration of the involvement of FcγRIIb in 
lupus pathogenesis was dramatically demonstrated in both the NZM2410 and BXSB 
models, in which full disease abrogation was achieved by partial restoration of 
FcγRIIb expression on hematopoeitic cells.11  
 
The B6.Sle1 congenic interval corresponds to the 37 cM long telomeric end of 
chromosome 1 derived from the NZM2410/NZW genome.12 The location within this 
interval of the Fcgr2b gene makes this the primary observed on B6.Sle1 GC B 
cells.10  However, it is not clear whether the polymorphisms in the FcγRIIb NZW allele 
alone are responsible for the perturbed expression of FcγRIIb on GC B cells in 
B6.Sle1 mice or whether other susceptibility genes located within the Sle1 interval 
might act epistatically in producing this altered expression. In addition, Fcgr2b is 
located between Sle1a and Sle1b, and we have reported that a congenic strain 
B6.Sle1(111–148) that contains Fcgr2b but lacks both Sle1a and Sle1b does not 
produce autoantibodies.
13 
The B6.Sle1(111–148) strain contains in addition to 
Fcgr2bNZW a number of genes of NZW origin, including two FcR homolog genes 
Fcrla and FcRlb. It however allows the evaluation of Fcgr2bNZW independently from 
Sle1a and Sle1b. In the present study, we report that Fcgr2bNZW fails to upregulate 
 on GC B cells independently from Sle1a and Sle1b, and that it is associated with a 
greater number of class-switched PCs in the spleen and bone marrow (BM).  
 
 
Results  
 
 
Perturbed upregulation of FcγRIIb expression on GC B cells in B6.Sle1 mice  
 
As previously described,
10 
we have established an operative definition of GC B-cell 
phenotype for flow cytometry using peptide nucleic acid (PNA), in combination with 
anti-B220 and anti-IgD. Based on B220 and PNA staining, we first separated B220hi 
mature B cells consisting of both PNA þ and PNAneg (rectangular gate, Figure 1a, left 
panel) populations from total lymphocytes obtained from sheep red blood cells 
(SRBC)-immunized C57BL/6 (B6) mice on day 9 of the immune response. We then 
defined B220
hi 
PNA
neg 
IgD þ and B220hi PNA þ IgDneg cells as non-GC and GC B 
cells, respectively (rectangular gates, Figure 1a, right panel).  
 
Using these definitions, we first measured the levels of FcγRIIb on splenic B-cell 
subpopulations, by performing four-color flow cytometry analysis from B6 and 
B6.Sle1 mice on day 9 of the anti-SRBC response. Fcgr2b-deficient (B6.RIIB-/-) mice 
were used as negative controls. The mAb 2.4G2 that recognizes the extracellular 
domains of both FcγRII and III was used since no mAb specific for the 
NZM2410/NZW/Sle1 FcγRIIb allele (Ly17.1 allotype) is available. As shown in Figure 
1b, compared with B220hi PNAneg IgD+ non-GC B cells (red line in histograms), the 
levels of 2.4G2 staining were elevated on B220hi PNAþ IgDneg GC B cells (blue line in 
histograms) in B6 mice (Figure 1b, lower left panel) while background levels of 
staining on both populations of B cells were observed in B6.RIIB-/-  mice (Figure 1b, 
right most panel). As previously described,10 and illustrated in Figure 1b, in contrast 
to splenic GC B cells in B6 mice (lower left panel), we found little or no elevation of 
2.4G2 staining levels on B6.Sle1 splenic GC B cells (blue line in histograms for 
B220hi PNAþ IgDneg cells, lower middle panel) as compared with non-GC B cells (red 
line in histograms, lower middle panel).  
 
We also investigated whether the altered expression of FcγRIIb we observed by flow 
cytometry on B6.Sle1 GC B cells was apparent on GC B cells and follicular dendritic 
cells (FDCs) were defined histologically.  Parallel spleen sections obtained on day 9 
post-SRBC immunization of B6, B6.Sle1 and B6.RIIB-/- mice were stained with 2.4G2 
and anti-IgD (Figure 1c, left panels) and FDC-M1 and GL7 (Figure 1c, right panels) 
to evaluate the expression of FcγRIIb on GC B cells and FDCs, respectively. 
Although 2.4G2 staining in B6 and B6.Sle1 GC FDC-rich regions was comparable, 
this staining was undetectable in B6.Sle1 GC areas deficient in FDCs. The 
background level of staining in both FDC-rich and FDC-poor regions of GCs in 
B6.RIIB
-/-
 mice indicated that FcγRIII is not expressed at levels detectable with 2.4G2 
on these cells. Together, these results confirmed our recently reported data showing 
 a defect in the upregulation of FcγRIIb expression on GC B cells in autoimmune-
prone B6.Sle1 mice.10  
 
The Fcgr2b allele in B6.Sle1(111–148) is of NZW origin  
 
We have already excluded Fcgr2b from the Sle1a and Sle1b intervals,13 but both 
these loci could interact with the Fcgr2bNZW allele and contribute to the failed FcγRIIb 
upregulation in Sle1 GC B cells. To test this hypothesis, we genotyped the two 
overlapping strains represented in Figure 2a: B6.Sle1a(15–353), previously 
associated with autoreactive T cells
14 
and B6.Sle1(111–148), previously described 
as not producing autoantibodies.13 A third intron deletion (Figure 2b) specific to the 
NZW allele10 determined that the Sle1a(15–353) interval contained the Fcgr2bB6 
allele, mapping the telomeric recombination breakpoint between D1MIT270 
(included) and Fcgr2b (excluded). In contrast, the Sle1(111–148) interval contained 
the Fcgr2bNZW allele, placing the telomeric recombination breakpoint between the 
Fcgr2b third intron (included) and D1MIT146 (excluded). We have not determined 
yet the exact location of the recombination breakpoint, and whether it is telomeric to 
the Fcgr2b promoter (Figure 2a, inset). The two strains also differed by their 
centromeric region centered on the D1MIT15 marker, where Sle1a was mapped.13 
 
The NZW origin of Fcgr2b in the B6.Sle1(111–148) strain was confirmed at the 
protein level. The mAb K9.361, which is specific for the FcγRIIb Ly17.2 allotype, was 
used to measure the levels of FcγRIIb on B-cell subpopulations. Four-color flow 
cytometry analysis of splenocytes obtained on day 9 of the anti-SRBC response 
revealed background levels of K9.361 staining on B6.Sle1(111–148) B-cell 
subpopulations as compared to the strong staining of B6 control and B6.Sle1a(15–
353) GC (blue line in histograms) and non-GC (red line in histograms) B cells (Figure 
3a). In addition, the levels of K9.361 staining on both B6 and B6.Sle1a(15–353) GC 
B cells were at least fivefold higher compared with their non-GC counterparts. We 
also performed histological analysis (Figure 3b) of spleen sections obtained on day 9 
of the anti-SRBC response by staining with anti-IgD (red) and K9.361 (green). While 
elevated levels of K9.361 staining were seen on IgDneg B cells in B6 and 
B6.Sle1a(15–353) GCs, this staining was undetectable in B6.Sle1(111–148) GCs, 
further supporting the conclusion that the Fcgr2b allele in B6.Sle1(111–148) mice is 
not of B6 but of NZW/NZM2410 origin. 
 
Failed upregulation of FcγRIIb on B6.Sle1(111–148) GC B cells 
 
Using the protocol described above, we evaluated the levels of FcγRIIb on GC and 
non-GC B-cell populations in splenocytes obtained on day 9 of the anti-SRBC 
responses of B6, B6.Sle1a(15–353) and B6.Sle1(111–148) mice (Figure 4a). In 
contrast to B6 GC B cells (blue line in histograms, lower left panel), little or no 
elevation of 2.4G2 staining levels was observed on B6.Sle1(111–148) GC B cells 
(blue line in histograms, lower right panel). Interestingly, however, we found levels of 
2.4G2 staining on B6.Sle1a(15–353) GC B cells at least eightfold higher than that on 
 non-GC B cells (Figure 4a, lower middle panel), analogous to that observed on B6 
splenic GCs.  
 
To corroborate these findings, we next performed histological analysis as described 
above in Figure 1c. As shown in Figure 4b, two sets of parallel spleen sections from 
each genotype were stained. Although 2.4G2 staining in the FDC-rich regions in 
GCs of all three strains was comparable, elevated levels of 2.4G2 staining was 
observed in the FDC-poor regions of B6 and B6.Sle1(15–353) GCs as compared to 
substantially lower or undetectable levels of staining in these regions in 
B6.Sle1(111–148) GCs (shown in arrows, right most column), analogous to that 
observed in B6.Sle1 GCs (Figure 1c). 
 
Staining of B6.RIIB-/- mice indicated that the mAb 2.4G2 predominantly detects 
FcγRIIb expression on GC B cells. Nonetheless, since this mAb recognizes the 
extracellular domains of both FcγRIIb and FcγRIII, a fraction of the 2.4G2 staining 
differences observed in B6.Sle1 or B6.Sle1(111–148) GCs could have resulted from 
altered expression of FcγRIII. Therefore, we sorted B220 þ PNA þ IgDneg GC B cells 
obtained on day 9 of the SRBC response and measured Fcgr2b mRNA levels via 
real-time RT-PCR. Fcgr2b mRNA levels in B6.Sle1(111–148) GC B cells were 
threefold lower than those in B6 control and B6.Sle1(15–353) GC B cells (Figure 4c). 
In total, these data indicated a defect in the upregulation of FcγRIIb expression on 
B6.Sle1(111–148) GC B cells similar to that observed in the B6.Sle1 strain. 
 
The Fcgr2bNZW allele is associated with an increased IgG production 
 
We screened a new cohort of 10-to 12-month-old B6.Sle1(111–148) mice and 
confirmed as previously reported that these mice do not produce anti-chromatin or 
anti-dsDNA antibodies (data not shown). To further determine the functional 
consequences of the expression of the Fcgr2bNZW allele, we compared antibody 
levels in SRBC-immunized mice. There was no significant difference between the 
three strains in levels of either SRBC-specific IgM or total IgM (Figures 5a and d). In 
contrast, B6.Sle1(111–148) mice produced significantly higher levels of SRBC-
specific IgG and total IgG (Figures 5b and e). This resulted in a significantly skewed 
IgG/IgM ratio for both the response to the T-dependent antigen and the total 
circulating immunoglobulin (Figures 5c and f).  
 
We have recently demonstrated that Fcgr2b deficiency regulated the production of 
autoreactive primary anti-production body-forming cells (AFCs) by BCR transgenic B 
cells independent of GC events.15 We, therefore, compared the effect of the Fcgr2b 
NZW and B6 alleles on AFC formation 6 and 14 days after SRBC immunization. At 6 
days in the spleen and 14 days in the BM, FcγRIIb expression on AFCs mirrored that 
on GC B cells with a significantly reduced level associated with the NZW allele 
(Figure 6a). Surface IgM expression on both CD138+ B220+  plasmablasts and 
CD138+ B220-/lo PC was significantly lower in B6.Sle1(111–148) than in either B6 or 
B6.Sle1a(15–353) mice (data not shown). Consistent with the surface expression, 
the percentage of intra- cellular IgM+ was also significantly lower in both splenic and 
 BM PCs at 6 and 14 days post immunization (p.i.) (Figure 6b), while the percentage 
of intracellular IgG+ PCs was significantly higher in B6.Sle1(111–148) spleens at 6 
days p.i. (Figure 6c). Finally, the percentage of total CD138+ B220-/lo  PCs was 
significantly higher in B6.Sle1(111–148) spleens at 6 and 14 days p.i. and BM 6 days 
p.i. (data not shown). These results were confirmed by the presence of a larger 
number of IgG+ AFCs in the spleen (although it did not reach statistical significance) 
and the BM (Po0.03) at 6 days p.i. in B6.Sle1(111–148) mice (Figure 6d). The same 
type of analysis was performed on mice following secondary immunization, and we 
did not observe any specific difference in B6.Sle1(111–148) mice (data not shown). 
Together, these data suggest that Fcgr2bNZW regulates the primary AFC pathway by 
increasing their number and by accelerating class switching. 
 
 
Discussion  
We have used NZM2410/NZW-derived congenic strains to analyze the phenotypes 
associated with the Fcgr2bNZW allele independently from the flanking lupus suscept-
ibility loci Sle1a and Sle1b. We have used a combination of genomic, transcriptional 
and histological methods to show that the 2–3 Mb congenic interval of B6.Sle1(111– 
148) contains the NZW allele of Fcgr2b, while the strain B6.Sle1a(15–353) that we 
have used previously to analyze Sle1a phenotypes contains the B6 allele of Fcgr2b.  
 
As we have previously described for the NZW and B6.Sle1 strains,10 B6.Sle1(111–
148) B cells fail to upregulate FcγRIIb at the GC stage, indicating that this phenotype 
does not require the expression of the Sle1a and Sle1b loci. The B6.Sle1(111–148) 
interval contains 15 other transcripts of known  genes (www.ensembl.org/  
Mus_musculus/ based on the NCBI m36 mouse assembly). At least 12 of these 
genes are shared with B6.Sle1a(15–353) and can, therefore, be excluded from 
impacting Fcrg2b expression. There are, however, two FcR homolog genes Fcrla 
(Freb2)16 and Fcrlb (FcRY or Freb1)17 that are contained in the B6.Sle1(111–148) 
interval, and potentially not in the B6.Sle1a(15–353) interval since they are situated 
in the region of recombination between the D1MIT270 and D1MIT147 markers. 
These two FcR family members are differentially expressed on B cells, including GC 
B cells, but their function is yet unknown.
18,19 
Interestingly, FCRL3,a member of this 
family in humans, is associated with RA and other autoimmune conditions, including 
lupus.20 We are currently investigating whether one or both of these genes present 
allelic differences between NZW and B6. If it were the case, it would be possible that 
these genes could indirectly regulate Fcrg2b on GC B cells. The most likely 
explanation, however, is that the failure to upregulate Fcgr2b expression on GC B 
cells is regulated in cis by the Fcgr2b NZW allele. 
 
In spite of the low expression of FcγRIIb on GC B cells, the number and size of GCs 
were equivalent between B6.Sle1(111–148) and B6 mice. We have found, however, 
that B6.Sle1(111–148) mice produced significantly more anti-SRBC IgG and total 
IgG, which was correlated with a greater number of primary AFCs that 
downregulated surface and intracellular IgM in favor of IgG. We have confirmed 
 recent results showing FcγRIIb expression on PC,21 but contrary to the other 
autoimmune strains NZB and MRL in which FcγRIIb is virtually absent on the PC 
surface, the NZW allele is associated with only a modest reduction of expression on 
PCs. Future experiments will have to be performed to assess whether this modest 
reduction is sufficient to decrease PC turnover through decreased apoptosis in 
Fcgr2bNZW-carrying mice, as it has been shown for Fcgr2b-deficient mice.21 
Interestingly, the kinetics of FcγRIIb expression on PC as well as the absence of 
Fcgr2bNZW-specific phenotype in secondary immune responses corroborates our 
previous findings15 that this receptor regulates allele does not result by itself in the 
production of primary T-dependent immune responses.  
 
Overall, our results indicate that Fcgr2bNZW functions an Fcgr2b hypomorph in 
regulating AFC numbers and class switching independent of GC reactions. This 
concurs with previous findings that showed that an Fcgr2b deficiency allows the 
accumulation of autoreactive PC.7,10 Interestingly, however, the Fcgr2b NZW allele 
does not result by itself in the production of autoreactive B cells, but acts as a 
modifier of the fate of autoreactive B cells induced by the expression of other as loci. 
It is not clear to what extent primary AFC foci contribute to systemic autoimmunity. 
However, at least in the MRL/lpr model, autoreactive B cells expand and 
hypermutate outside of GCs,22 which suggests that primary AFCs constitute a key 
regulatory pathway in the maintenance of B-cell tolerance. We are in the process of 
testing whether a similar GC ‘bypass’ also occurs in the NZM2410 strain, and what 
role, if any, Fcgr2b plays in this context.  
 
We have previously documented the highly interactive nature of the Sle1 loci,23 and 
we have specifically shown that the interval including Sle1a, Sle1b and the inter-
vening region resulted in autoimmune phenotypes that were much stronger than the 
simple additive effects of Sle1a plus Sle1b. We speculate that Fcgr2bNZW contributes 
to these epistatic effects. In addition, we have previously shown that both NZM2410 
and NZW mice present an accumulation of PC in the spleen.24 Although we were not 
able to map the entire phenotype to any single Sle locus, it is also temping to 
speculate that reduced FcγRIIb expression may contribute to this phenotype, as 
suggested by our data in Figure 6. Interestingly, close examination of our results in 
Figures 5 and 6 suggests that Sle1a also impacts the immune response to SRBC 
immunization, including the number of class-switched PCs. Detailed studies of the 
interaction between Fcgr2bNZW and the other Sle loci in the context of plasma cell 
development will be necessary to fully understand how the restoration of normal 
FcγRIIb expression on NZM2410 B cells was sufficient to abrogate disease.11 
 
 
Materials and methods  
 
Mice and immunization  
 
The B6.NZM2410-Sle1 (B6.Sle1), B6.NZM2410-Sle1a(15– 353) (B6.Sle1a(15–353)) 
 and B6.NZM2410-Sle1(111–148) (B6.Sle1(111–148)) mice have already been 
described.
12,13 
These mice along with B6 controls were bred at the University of 
Florida Animal Care Center. B6;129S4Fcgr2btm1Rav/J (B6.RIIB-/-) were kindly supplied 
by Dr Jeffrey Ravetch (The Rockefeller University, New York, NY, USA). All mice 
were maintained in a pathogen-free barrier facility and all procedures were approved 
by the JU or UF IACUCs. Cohorts of at least three mice per strain were immunized 
intra-peritoneally with 200 µl of SRBC diluted 10% v/v in sterile 0.9% saline solution. 
Spleens, BM and terminal sera were collected after either 6, 9, or 14 days, as 
indicated in the text. All mice were used between 8 and 20 weeks of age, except for 
the autoantibody screens, and cohorts of both males and females were used without 
significant differences. 
 
Congenic strain genotyping  
 
All available MIT microsatellite markers located within 170 and 173 Mb on 
chromosome 1 were screened for polymorphism between B6 and NZW and then 
used to assess the haplotype distribution across the B6.Sle1a(15– 353) and 
B6.Sle1(111–148) intervals. The NZW or B6 allelic origin of the Fcgr2b gene was 
determined with PCR primers designed to detect the 4921–4944 deletion in the third 
intron (region 4 described by Rahman and Manser10). The sequences were for the 
sense primer: 5′-TGCCCCCTCCTCTTATCC and 5′-TGCATGTATGTG CATGTGT 
for the antisense primer. 
 
Antibodies and other reagents  
 
Antibodies and other reagents used for flow cytometry and immunohistology 
included the following: PE, fluorescein isothiocyanate (FITC) and PE-Texas red-anti-
B220 (clone RA3–6B2); PE-anti-FcγRII/FcγRIII (clone 2.4G2); PE-anti-IgD (clones 
11–26); APC-anti-IgM (clone Igh6); biotin-anti-CD138 (clones 281–282), Streptavidin 
(SA)-CyChrome; rat IgG Ab to mouse FDCs (FDC-M1, BD Pharmingen, San Diego, 
CA, USA); biotin-anti-IgD (clones 11–26, Southern Biotechnology Associates, 
Birmingham, AL, USA); FITC-goat anti-mouse IgG (Southern Biotechnology); SA-
PE; avidin-Alexa Fluor 488 (Molecular Probes, Eugene, OR, USA); FITC-peanut 
lectin (agglutinin, PNA, Vector Laboratories, Burlingame, CA, USA); biotin-(Fab′)2 
mouse anti-rat IgG (Jackson Immunoresearch Laboratories, West Grove, PA, USA). 
The K9.361 mAb was biotinylated in house from the hybridoma kindly provided by Dr 
U Hammerling (Sloan-Kettering Memorial Hospital, New York, NY, USA). 
Intracellular staining was performed with BD Pharmingen reagents as recommended 
by the manufacturer. 
 
Immunohistology  
 
Spleen cryostat sections (5–6 mm) were prepared as described.25 Immunohistology 
was performed using the antibodies listed above and the stained sections were 
analyzed using a fluorescence microscopy (Leitz Diaplan, Wetzlar, Germany) and 
images were captured as described.26  
  
Flow cytometry  
 
Four-color flow cytometric analysis was performed on cell suspensions prepared 
from spleens of naive and immunized mice stained with multiple combinations of 
antibodies listed above. Biotinylated Abs were detected with SA-CyChrome. Stained 
cells were analyzed using a Coulter Epics XL/MCL or a Facscalibur (BD 
Biosciences) analyzer. Data were analyzed using the FlowJo software (Treestar, 
San Carlos, CA, USA).  
 
GC B-cell sorting, RNA extraction and real-time RT–PCR  
 
B220high IgDneg PNA+ GC B cells were sorted using a MoFlo fluorescent activated 
high-speed sorter (Dako Cytomation, Glostrup, Denmark). RNA purification, reverse 
transcription of RNA, real-time RT-PCR and generating raw RQ (relative 
quantification) values for FcγRIIb gene expression in GC B cells were performed as 
described.10  
 
Antibody measurements  
 
All antibodies were detected by enzyme-linked immunosorbent assay (ELISA) in 
Immunolon II plates (Dynex, Chantilly, VA, USA). For anti-SRBC antibodies, the 
plates were coated with SRBC diluted at 1:1000 in PBS for 1 h at room temperature, 
then fixed with 0.5% gluteraldehyde. After blocking (3% BSA, 0.1% gelatin, 3 mM 
EDTA), sera were incubated in duplicate at 1:200 dilution for 2 h, and bound IgG 
antibodies were detected with an alkaline phosphatase-conjugated goat anti-mouse 
IgG antibody (Chemicon International, Temecula, CA, USA) at a 1:1000 dilution. 
Total IgM and IgG were detected by sandwich ELISA with sera diluted 1:200 000 as 
previously described.27 Anti-chromatin IgG antibodies were detected in 10-to 12-
month-old mice with plates coated with total histone and dsDNA as previously 
described.28  
 
Enzyme-linked immunospot (ELISPOT) assay  
 
AFCs were enumerated by ELISPOT as previously described.24 Serially diluted RBC-
depleted spleen and BM cells were added to multiscreen filter plates (Millipore, MA, 
USA) coated with 5 µg/ml goat anti-mouse IgG for 6 h at 37 1C. Bound cells were 
detected with HRP-conjugated-anti-IgG (Southern Biotechnology), and developed by 
3-amino-9-ethylcarbazole (AEC, Sigma-Aldrich, St Louis, MO, USA). AFCs were 
then counted and measured using a Bioreader 4000 Pro-x (BioSys, Germany).  
 
Statistical analysis  
 
Statistical significance was evaluated with the GraphPad Prism 4 software package 
and the specific tests were reported in the text (either Bonferroni’s multiple 
comparison or variance F tests).  
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 Figures & Captions 
 
 
 
Figure 1 
 
FcγRIIB expression on germinal center (GC) B cells and follicular dendritic cells 
(FDCs) in C57BL/6 and b6.Sle1 mice. 
 
(a) Splenocytes from sheep red blood cells (SRBC)-immunized B6 mice on day 9 
of the immune response were stained with peptide nucleic acid (PNA), in 
combination with anti-B220 and anti-IgD and analyzed by flow cytometry. In 
the left panel, B220hi and PNA+ /PNAneg mature cells are shown in the 
rectangular gate. In the right panel, B220hi PNA+ /IgDneg GC and B220high 
PNAneg IgDþ non-GC B cells are shown in two rectangular gates.  
 
(b) Levels of FcγRIIb measured by staining with 2.4G2 (bottom row) on B220hi 
PNA+ /IgDneg GC (blue histograms) and B220hi PNAneg IgDþ non-GC (red 
histograms) B cells are shown for SRBC-immunized B6, B6.Sle1 and B6.RIIB-
/-
 mice on day 9 of the primary GC response.  
 
(c) (c) Adjacent spleen sections obtained from these mice were stained with 
2.4G2 (red) and anti-IgD (green), shown in the left column and FDC-M1 (red) 
and GL7 (green), shown in the right column. These data represent those 
obtained from three to five mice of each strain. 
 
  
 
 
 Figure 2  
 
The B6.Sle1a(15–353) and B6.Sle1(111–148) congenic strains differ by the 
B6 or NZW origin of Fcgr2b. 
 
(a) Map of the two congenic intervals with, from top to bottom, the distance in 
Mb, the position of key polymorphic microsatellite markers used to define the 
interval termini, the position of the Fcgr2b gene and the two intervals. The 
gray bars represent the areas of known NZW (NZM2410) derivation, and the 
white bars represent the areas of recombination between the NZW and B6 
genomes. The boxed inset on the right shows an enlargement of the 
telomeric termini between markers D1MIT147 and D1MIT146 relative to the 
Fcg2rb transcript.  
 
(b) PCR amplification of the region 4 deletion identifying the NZW allele in 
B6.Sle1(111–148) as compared to B6.Sle1a(15–353), which has the B6 
alleles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3  
 
B6.Sle1(111–148) mice contain a Fcgr2b allele of NZW origin.  
 
(a) Splenocytes from sheep red blood cells (SRBC)-immunized B6, B6.Sle1a(15–
353) and B6.Sle1(111–148) mice obtained on day 9 of the immune response were 
stained with peptide nucleic acid (PNA), in combination with anti-B220 and anti-IgD. 
Levels of FcγRIIb measured by the mAb K9.361 that specifically stains the Fcgr2b 
allele of B6 origin (Ly17.2 allotype) on B220hi PNAþ /IgDneg germinal center (GC) 
(blue histograms) and B220hi PNAneg IgDþ non-GC (red histograms) B cells are 
shown. 
 
 (b) Spleen sections obtained on day 9 of the anti-SRBC response of B6, 
B6.Sle1a(15–353) and B6.Sle1(111–148) mice were stained with anti-IgD (red) and 
K9.361 (green). These data are representative of at least three mice of each 
genotype.  
 
 
  
 
 
 
 
 
 
 
Figure 4  
 
Impaired FcγRIIb expression on B cells and follicular dendritic cells (FDCs) in 
B6.Sle1(111–148), but not in B6.Sle1a(15–353) mice.  
 
(a) Splenocytes obtained on day 9 of the anti-sheep red blood cells (SRBC) 
response of B6, B6.Sle1a(15–353) and B6.Sle1(111–148) mice were stained and 
analyzed, and data are illustrated as detailed in Figures 1a and b.  
 
(b) Two sets of adjacent spleen sections obtained on day 9 of the anti-SRBC 
response of B6, B6.Sle1a(15–353) and B6.Sle1(111–148) mice were stained and 
illustrated as detailed in the legend to Figure 1c. Substantially lower or undetectable 
levels of 2.4G2 staining, in IgD- GL7þ and FDC poor regions in B6.Sle1(111–148) 
GCs, are shown by arrows, right most column. These data are representative from 
five to seven mice of each genotype. (c) RNA was extracted from FACS-purified 
B220hi PNA+ /IgDneg germinal center (GC) B cells obtained on day 9 of the SRBC 
response of B6, B6.Sle1a(15–353) and B6.Sle1(111– 148) mice. Raw RQ values of 
Fcgr2b expression in B6 (open bar), B6.Sle1a(15–353) (green bar) and 
B6.Sle1(111–148) (red bar) GC B cells were obtained via real-time RT-PCR by 
setting the RQ value for B6 GC B cells as 1. Real-time RT-PCR amplification was 
performed in quadruplet, from which the means and maximum relative quantification 
(RQ as calculated by the ABI software) shown as error bars were generated. These 
data are representative of pooled samples of two to three mice of each genotype 
obtained from three experiments.  
 
  
 
 
 
 
  
Figure 5 
 
IgG production is increased in B6.Sle1a(111–148) mice.  
 
Anti-sheep red blood cell (SRBC) IgM (a) and IgG (b) antibodies, as well as total IgM 
(d) and IgG (e) were measured on day 9 after primary immunization in the three 
congenic strains. The graphs on the right show the anti-SBRC (c) and total (f) 
IgG/IgM ratios. Each symbol represents a mouse. **P < 0.01; ***P < 0.001 from 
Bonferroni’s multiple comparison tests.  
 
 
 
 
Figure 6 
 
B6.Sle1(111–148) antibody-forming cells (AFCs) produce less IgM and more IgG 
than congenic mice carrying the Fcgr2b B6 allele.  
 
Splenic (graphs on the left) and bone marrow (BM) (graphs on the right) CD138+ 
B220-/lo plasma cells (PC) were evaluated in 6 and 14 days after sheep red blood 
cells (SRBC) immunization.  
 
(a) Surface FcγRIIb expression.  
 
(b) Intracellular IgM expression.  
 
(c) Intracellular IgG expression.  
 
(d) Number of IgG þ AFC measured by ELISPOT. Mean and s.d. of six mice (6 days 
p.i.) and three mice (14 days p.i.) per strain. *P < 0.05; **P < 0.01 from Bonferroni’s 
multiple comparison tests. Representative flow cytometry histograms gated on 
CD138+ B220-/lo  PC in the spleen 6 days p.i. are shown on the right, with filled gray 
 histograms representing C57BL/6, and solid and broken lines representing 
B6.Sle1(111–148) and B6.Sle1a(15–353), respectively.  
 
 
 
 
 
 
